{"filings":[{"id":94593,"accession_number":"0001193125-26-204147","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Q1 2026: net loss narrows to $122.9M; CASGEVY revenue $43M; cash at $2.44B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $122.9M vs $136.0M in Q1 2025; R&D spend $68.6M, G&A $17.2M.","CASGEVY revenue of $43M; collaboration expense net $45.9M, down on higher revenue share.","Cash, equivalents and securities $2,441.8M, up from $1,975.8M, boosted by $585.4M convertible note.","Zugo-cel started 3rd Phase 1 in autoimmune neurology; SLE patients remain in DORIS remission at Month 12 and Month 6.","In vivo CTX310 IND cleared for US; CTX460 (AATD) and CTX340 (hypertension) on track for mid-2026 and H1 2026 clinical starts."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1458000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107093,"accession_number":"0001193125-26-108333","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics completes $600M convertible note offering due 2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600M aggregate principal of Convertible Senior Notes due 2031; net proceeds ~$585.2M.","Effective coupon 1.125%; increased to 1.7308% due to anticipated Swiss withholding tax.","Initial conversion price ~$76.56 per share, a 45% premium to the $52.80 closing price on March 10, 2026.","Notes mature March 1, 2031; unregistered, sold to QIBs under Rule 144A; proceeds for general corporate purposes.","Holders may convert at any time before maturity; company may redeem after March 6, 2029 if stock price condition met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107092,"accession_number":"0001193125-26-101073","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CRISPR Therapeutics prices $550M convertible notes due 2031 at 1.125% coupon","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal amount upsized from $350M to $550M; net proceeds estimated at ~$536.3M.","Notes mature March 1, 2031; effective coupon 1.125% (1.7308% after Swiss withholding adjustment).","Initial conversion price ~$76.56 per share, a 45% premium over $52.80 closing price on March 10, 2026.","Holders may convert at any time prior to maturity; company may redeem after March 6, 2029 under certain conditions.","Proceeds for general corporate purposes; closing expected March 16, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107091,"accession_number":"0001193125-26-048873","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q4 2025 net loss $130.6M; CASGEVY Q4 revenue $54M, full year $116M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $130.6M in Q4 2025 vs $37.3M loss in Q4 2024; collaboration expense increased to $53.7M.","CASGEVY revenue $54M in Q4, $116M full year 2025; 64 patients infused during the year (30 in Q4).","Cash, cash equivalents and marketable securities $1,975.8M as of Dec 31, 2025, vs $1,903.8M Dec 31, 2024.","R&D expenses $83.5M (Q4 2025) vs $71.7M (Q4 2024); G&A $18.4M vs $18.1M.","Pediatric CASGEVY submissions for ages 5-11 expected H1 2026; in vivo programs CTX460 (mid-2026) and CTX340 (H1 2026) to enter clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":3510000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107090,"accession_number":"0001193125-26-009880","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CRISPR Therapeutics provides pipeline update: CTX310 advances to Phase 1b; zugo-cel shows durable remission in SLE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CTX310 (ANGPTL3) advanced to Phase 1b for severe hypertriglyceridemia and refractory hypercholesterolemia after positive Phase 1 data.","CTX320 (LPA) showed up to 73% reduction in dose escalation; next-gen CTX321 with ~2-fold greater potency in preclinical testing.","Zugo-cel (CTX112): first SLE patient in drug-free DORIS remission at month 9; second SLE patient with SLEDAI-2K 0 at month 2.","Collaboration with Eli Lilly to evaluate zugo-cel + pirtobrutinib in aggressive B-cell lymphomas.","Next-gen diabetes candidate CTX213 progressing towards clinic after promising CTX211 data showing C-peptide at 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123431,"accession_number":"0001193125-25-273329","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q3 net loss widens to $106M; CASGEVY momentum builds, CTX310 Phase 1 data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $106.4M vs $85.9M YoY; cash & equivalents $1.94B (flat vs Dec 2024).","CASGEVY: 165 patients completed cell collection, 39 infused; Vertex expects >$100M revenue in 2025.","CTX310 Phase 1 data at AHA/NEJM show durable TG and LDL reduction; advancing to Phase 1b.","CTX460 (SyNTase) preclinical data >90% mRNA correction in AATD; trial planned mid-2026.","SRSD107 Phase 2 first patient dosed for thromboembolic disorders; trial expanded in Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":2646000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123430,"accession_number":"0001193125-25-240282","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CRISPR Therapeutics files $600M ATM offering through Jefferies","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement to sell up to $600M of common shares at-the-market.","Offering uses existing shelf registration (Form S-3ASR filed Aug 5, 2024).","Jefferies LLC acts as sole sales agent; shares sold at company's discretion.","Legal opinion of Walder Wyss AG filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140095,"accession_number":"0000950170-25-102027","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q2 net loss $208.5M; CASGEVY hits 75 ATCs, 115 cell collections; CTX310 shows 86% LDL reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $208.5M in Q2 2025 vs $126.4M in Q2 2024; cash & securities $1.72B down from $1.90B at end-2024.","CASGEVY momentum: >75 authorized treatment centers activated, ~115 patients had cells collected, 29 received infusions (16 in Q2).","CTX310 Phase 1 data: dose-dependent TG reduction up to 82% and LDL reduction up to 86% after single administration; full data H2 2025.","EMA authorized Phase 2 trial for SRSD107 (Factor XI siRNA) in thromboembolic disorders; $25M upfront to partner Sirius Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":1757000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157748,"accession_number":"0000950170-25-090170","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CRISPR Therapeutics reports up to 86% LDL reduction with CTX310; delays CTX320 data to H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CTX310 Phase 1 shows up to 82% TG and 86% LDL reductions at 0.8 mg/kg with stable liver enzymes.","CTX320 (LPA gene) Phase 1 data update expected in first half of 2026 due to strategic pause for Lp(a) landscape insights.","CTX340 (AGT gene) for refractory hypertension advancing through IND/CTA-enabling studies.","CTX310 trial enrolling HoFH, severe hypertriglyceridemia, HeFH, and mixed dyslipidemia patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157747,"accession_number":"0000950170-25-083799","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"CRISPR Therapeutics shareholders elect new director, approve board size increase at 2025 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New director Briggs W. Morrison, M.D. elected; board size maximum increased.","Binding votes on executive compensation approved with significant against votes (e.g., equity grant for execs: 31.8M for, 9.0M against).","Non-binding advisory vote on named executive officer compensation passed with 29.1M for vs 11.7M against.","Shareholders approved amendments to articles of association, effective June 6, 2025, subject to Swiss registration.","All director nominees re-elected; auditors Ernst & Young re-elected for FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157746,"accession_number":"0000950170-25-074428","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CRISPR Therapeutics enters collaboration with Sirius on FXI-targeting siRNA; positive Phase 1 data","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration: $70M in common shares + $25M cash to Sirius for co-development of FXI-targeting siRNA SRSD107.","Potential milestones: up to $340M for opt-out and up to $87.5M for development/regulatory; royalties mid-single to low-double digit.","Phase 1: single doses well tolerated, >93% reduction in FXI levels and activity, sustained up to six months post-dosing.","Phase 2 trial initiated for prevention of venous thromboembolism in patients undergoing total knee arthroplasty.","Company has options to exclusively license Sirius siRNA technology for up to two additional targets; $10M option fee per target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157745,"accession_number":"0000950170-25-064435","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q1 2025 net loss $136M; CTX310 Phase 1 shows up to 82% TG reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $136.0M in Q1 2025, compared to $116.6M in Q1 2024; cash & equivalents $1.86B.","CTX310 Phase 1 data: dose-dependent reductions in LDL (up to 81%) and TG (up to 82%) with well-tolerated safety.","CASGEVY: >65 authorized treatment centers activated; ~90 patients with first cell collection; new initiations to grow in 2025.","R&D expenses $72.5M, G&A $19.3M; collaboration expense net $57.5M (driven by CASGEVY and in vivo HSC editing).","CTX320 (Lp(a)) dose escalation ongoing with update expected Q2 2025; CTX112/CTX131 CAR T updates mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":865000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176114,"accession_number":"0000950170-25-045232","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CRSP COO Julianne Bruno steps down effective April 11, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Julianne Bruno resigns as COO of CRISPR Therapeutics to pursue external opportunities.","Departure effective April 11, 2025; she remains an employee until that date.","Resignation not the result of any disagreement with the company.","CEO Samarth Kulkarni thanked Bruno for six years of leadership in hematology and oncology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176113,"accession_number":"0000950170-25-017879","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q4 net loss $37.3M; cash at $1.9B; 50+ ATCs activated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss of $37.3M vs net income of $89.3M in Q4 2023.","Cash, cash equivalents, and marketable securities of $1,903.8M, up from $1,695.7M a year earlier.","Over 50 authorized treatment centers activated globally for CASGEVY; >50 patients have had cells collected.","R&D expenses fell to $82.2M in Q4 2024 from $95.1M in Q4 2023.","Pipeline catalysts in 2025: CTX112 updates mid-2025; CTX310/320 updates H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":37314000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193020,"accession_number":"0000950170-24-121103","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR reports Q3 net loss $85.9M; CASGEVY now approved in Switzerland and Canada","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $85.9M in Q3 2024 vs $112.2M loss in Q3 2023; cash and securities $1.935B as of Sept 30.","CASGEVY approved for SCD and TDT in Switzerland and Canada; 45 ATCs activated globally.","Approximately 40 patients have had cell collections across all regions as of mid-October.","CTX112 Phase 1 data to be presented at ASH 2024: 67% ORR, 44% CRR in lymphoma patients.","R&D expenses $82.2M (down from $90.7M); collaboration expense net $11.2M (down from $23.4M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":1623000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209390,"accession_number":"0000950170-24-090727","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q2 2024 net loss widens to $126.4M; CASGEVY launch with 35+ ATCs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $126.4M vs $77.7M in Q2 2023; R&D expenses down to $80.2M from $101.6M.","Cash, equivalents and securities $2.01B as of June 30, up from $1.70B at Dec 31, 2023.","CASGEVY: >35 ATCs activated globally; ~20 patients have had cells collected as of mid-July.","CTX112 CD19 CAR T Phase 1/2 trial opened for SLE; preliminary oncology data expected this year.","Appointed Naimish Patel as CMO; promoted Julianne Bruno to COO and Susan Kim to SVP IR."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":1021000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227401,"accession_number":"0000950170-24-067660","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"CRISPR Therapeutics shareholders approve 1M share increase to equity plan, elect two new directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to 2018 Stock Option Plan adding 1,000,000 common shares to reserve approved (34.3M for, 8.5M against).","Sandesh Mahatme and Christian Rommel elected as new Board members; all incumbent directors re-elected.","Articles of Association amended: capital band increased to CHF 3,100,452; equity/pension practices updated.","Binding vote on Board equity grants passed 32.2M for vs 10.7M against; 2023 compensation report endorsed non-binding.","Proposal to transact other business was rejected (21.9M against, 20.3M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227400,"accession_number":"0000950123-24-005877","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics appoints Julianne Bruno as COO effective May 23, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruno previously SVP and Head of Programs & Portfolio; led hemoglobinopathy partnership with Vertex.","Annual salary of $460,000, target bonus 45% of base, and eligible for equity plans.","Received one-time grant of 20,000 RSUs vesting over 4 years (25% annually).","Employment agreement provides 6-month notice period; 12-month notice and accelerated vesting after change in control.","Bruno holds MBA from Wharton, AB from Princeton; prior McKinsey biotech practice leader."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227399,"accession_number":"0000950170-24-055689","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q1 net loss widens to $116.6M; cash $2.1B after $280M offering and $200M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $116.6M in Q1 2024 vs $53.1M in Q1 2023; R&D expenses fell 24% to $76.2M.","Ended March with $2.1B cash; includes $280M February direct offering and $200M CASGEVY milestone from Vertex.","CASGEVY now approved in 5 regions; over 25 ATCs activated globally, multiple patients have cells collected.","Next-gen CAR T CTX112 (CD19) and CTX131 (CD70) trials ongoing; preliminary CTX112 data expected this year.","New in vivo programs CTX340 (hypertension) and CTX450 (porphyria) enter IND-enabling studies; clinical trials targeted for H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":504000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}